Related Experiment Video
Updated: Jun 17, 2026
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
Antibody-based vascular tumor targeting
Christoph Schliemann1, Dario Neri
1Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology Zürich, Zürich, Switzerland.
Abstract:
The inhibition of angiogenesis represents a major step toward a more selective and better-tolerated therapy of cancer. An alternative way to take advantage of a tumor's absolute dependence on a functional neovasculature is illustrated by the strategy of "antibody-based vascular tumor targeting." This technology aims at the selective delivery of bioactive molecules to the tumor site by their conjugation to a carrier antibody reactive with a tumor-associated vascular antigen. A number of high-affinity monoclonal antibodies are nowadays available which have demonstrated a remarkable ability to selectively localize to the tumor vasculature. Indeed, some of them have already progressed from preclinical animal experiments to clinical studies in patients with cancer, acting as vehicles for the site-specific pharmacodelivery of proinflammatory cytokines or radionuclides.In this chapter, we present a selection of well-characterized markers of angiogenesis which have proven to be suitable targets for antibody-based vascular targeting approaches. Furthermore, different transcriptomic and proteomic methodologies for the discovery of novel vascular tumor markers are described. In the last two sections, we focus on the discussion of antibody-based vascular tumor targeting strategies for imaging and therapy applications in oncology.
Insights
Targeting tumor vasculature with antibodies offers a novel cancer therapy approach. This strategy selectively delivers drugs to tumors by targeting angiogenesis markers, improving cancer treatment selectivity and tolerability.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Cancer therapy increasingly focuses on inhibiting angiogenesis, the formation of new blood vessels essential for tumor growth.
- Antibody-based vascular tumor targeting leverages tumors' dependence on neovasculature for selective drug delivery.
Purpose of the Study:
- To review suitable angiogenesis markers for antibody-based vascular targeting.
- To describe transcriptomic and proteomic methods for discovering new vascular tumor markers.
- To discuss antibody-based vascular targeting strategies for cancer imaging and therapy.
Main Methods:
- Selection of well-characterized angiogenesis markers.
- Application of transcriptomic and proteomic methodologies for marker discovery.
- Review of existing antibody-based vascular targeting strategies.
Main Results:
- Several angiogenesis markers are suitable targets for antibody-based vascular targeting.
- Transcriptomic and proteomic approaches can identify novel vascular tumor markers.
- Antibody-based strategies are progressing in preclinical and clinical cancer studies.
Conclusions:
- Antibody-based vascular tumor targeting is a promising strategy for selective cancer therapy and imaging.
- Targeting tumor vasculature offers a more selective and better-tolerated approach to cancer treatment.
- Continued research into novel markers and targeting strategies will advance oncological applications.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...